Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio ...
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
Swedish Orphan Biovitrum engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. It offers drugs for the treatment of rare and life-threatening diseases, such as cardiology, diseases affecting immunocompromised patients, genetic disorders, haematology, infectious diseases, metabolic disorders, oncology, palliative care, poison control, respiratory diseases, and urology.
In 2009, Swedish Orphan International AB merged with [Biovitrum](/organization/biovitrum), and the combined company has subsequently been rebranded as Swedish Orphan Biovitrum. The company markets its products in Europe, North American, and Japan and is headquartered in Stockholm, Sweden.
Join Apollo to reach decision makers at Sobi - Swedish Orphan Biovitrum AB (publ)